A151804 Biorepository (Cancers Treated with Immunotherapy)

Purpose of this Study

We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with cancer and have not previously been treated with CTLA-4, PD-1, or PD-L1 inhibitors
  • Received a regimen containing one or more immuno-oncology therapeutics
  • Experienced one or more serious AEs during treatment
  • Have not previously been registered to this study
For more information, contact the study team at nick.jeffries@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

You can choose to join this study if you are receiving immunotherapy as part of your cancer treatment. You may enroll before or after experiencing one or more side effects.

Locations

Duke Raleigh Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

Yes

Study Details

Full Title

Alliance A151804 Establishment of a national biorepository to advance studies of immune-related adverse events

Principal Investigator

Tucker
Coston

Protocol Number

PRO00117018

NCT ID

NCT04242095

Phase

N/A

Enrollment Status

Open to Enrollment